📇 Rhumatologue · COMPIEGNE · (60) · Salarié
Chargement de la fiche…
Chargement de la fiche…
MonRhumato.fr utilise des cookies pour mesurer l'audience (statistiques) et améliorer le site. Aucune donnée de santé identifiable n'est jamais collectée. Politique de confidentialité.
Votre choix est conservé 13 mois (durée max CNIL). Vous pouvez le modifier à tout moment via Préférences cookies.
2 raisons identifiées
Praticien-chercheur
8 articles scientifiques publiés — formation continue solide
Délais de RDV courts dans la région
73.1 rhumatos / 100 000 hab. — département bien doté
✨ Génération du profil synthétique IA en cours…
EHPAD SAINT-JACQUES COMPIÈGNE
1 R DE LA SURVEILLANCE, 60200 COMPIEGNE
Secteur de conventionnement non disponible (médecin hospitalier ou non présent dans l'Annuaire santé CNAM des libéraux conventionnés).
Données ANS publiques (Licence Ouverte 2.0) · Enrichissements MonRhumato 100 % opt-in · Toute personne référencée peut demander la suppression ou la rectification.
Lien Doctolib = recherche Google site:doctolib.fr (le 1er résultat est presque toujours le profil correct s'il existe).
Biochemical and biophysical research communications · 1994
Internal medicine journal · 2013
AbstractBackground/AimSubjects with metabolic risk factors for non‐alcoholic fatty liver disease (NAFLD) are commonly seen by hospital specialists other than gastroenterologists/hepatologists. The aim of this study was to assess the awareness of NAFLD and opinions regarding management among non‐hepatologists at two major tertiary hospitals in Brisbane.MethodsA face‐to‐face questionnaire assessing current beliefs and practices regarding NAFLD was administered to specialists and specialists‐in‐training across six specialties (internal medicine, cardiology/cardiac surgery, endocrinology, thoracic medicine, rheumatology and nephrology).ResultsOne hundred clinicians were surveyed with 99% returning completed questionnaires (>89% questions answered). The majority of respondents (75%) believe the prevalence of NAFLD in the general population to be ≤10%, although two‐thirds feel that its incidence will rise markedly. The vast majority (>90%) appreciate that traditional cardiovascular risk factors (obesity, hypertriglyceridaemia and diabetes) are risk factors for NAFLD and acknowledge that these are common in non‐hepatology patients. Despite this, most believe that NAFLD is uncommon in their own patients (89% indicated a prevalence ≤30%). The vast majority (93%) agree that non‐alcoholic steatohepatitis (NASH) is associated with increased overall mortality, but 60% also believe that simple steatosis confers increased liver‐related mortality. Most (74%) agree that a diagnosis of NASH cannot be made using liver enzymes, but 67% support 6‐monthly liver function tests as the most effective way to monitor progression of NAFLD. Most respondents (71%) make no referrals to hepatology for suspected NAFLD.ConclusionsNon‐hepatologists appreciate the seriousness of NAFLD but appear to underestimate its prevalence, especially among their own patients despite known risk factors. Attitudes regarding simple steatosis versus NASH and appropriate monitoring of suspected NAFLD suggest that more can be done to improve the understanding of this disease among non‐hepatologists. This has implications for targeting ‘at‐risk’ populations and appropriate referral of patients to hepatology clinics.
Journal of gastroenterology and hepatology · 1999
Background: In this study, we determined whether low‐titre auto‐antibodies are a risk factor for the development of autoimmune disease during interferon‐α (IFNα) therapy for chronic hepatitis C (CHC) infection. Methods: Eighty‐three patients with circulating hepatitis C virus RNA and chronic viral hepatitis on liver biopsy, who had not received IFNα, were assessed for serum auto‐antibodies (anti‐nuclear antibodies (ANA), anti‐smooth muscle antibodies, thyroid microsomal antibodies, thyroglobulin antibodies) and thyroid function tests. Results: Thirty‐five patients had one or more pre‐existing auto‐antibody. The majority were low titre ANA. Seven of the 35 patients had clinical autoimmune disease or immune‐mediated disorders, predominantly thyroid disease. Twenty patients with low titre auto‐antibodies received treatment with IFNα and of these 20 patients, six patients developed adverse effects with a possible auto‐immune basis. In comparison, only five of the 48 patients without auto‐antibodies had immune‐mediated disorders and no patient developed autoimmune complications during therapy with IFNα. Conclusions: These results suggest that the presence of low‐titre auto‐antibodies may be a risk factor for the development of autoimmune dysfunction during IFNα therapy for chronic hepatitis C. Patients with no detectable auto‐antibodies have a low risk for developing autoimmune complications during treatment with IFNα.
Source PubMed · Recherche par auteur (homonymes possibles, vérifier l'affiliation).
Biomedicine & pharmacotherapy = Biomedecine & pharmacotherapie · 2025 · Journal Article
Frost K, Urbanowski A, Neag G, Lewis JW, et al.
Cell reports. Medicine · 2024 · Journal Article
Lewis JW, Frost K, Neag G, Wahid M, et al.
Diagnostic microbiology and infectious disease · 2019 · Case Reports
Khalil N, Corker L, Powell EA, Mortensen JE
Internal medicine journal · 2013 · Journal Article
Bergqvist CJ, Skoien R, Horsfall L, Clouston AD, et al.
Journal of gastroenterology and hepatology · 1999 · Journal Article
Bell TM, Bansal AS, Shorthouse C, Sandford N, et al.
Biochemical and biophysical research communications · 1994 · Journal Article
Ellis AJ, Curry VA, Powell EK, Cawston TE
Annals of internal medicine · 1989 · Case Reports
Yap AS, Powell EE, Yelland CE, Mortimer RH, et al.
Orthopedics · 2012 · Journal Article
France JC, Powell EN 2nd, Emery SE, Jones DL